Antibodies to TGF-beta 1
TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.
1. An antibody, or an antigen-binding fragment thereof, comprising:
a light chain variable region having the amino acid sequence shown in SEQ ID NO: 43 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 90, or
a light chain variable region having the amino acid sequence shown in SEQ ID NO: 146 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 117.
2. The antibody of claim 1 , comprising:
a light chain having the amino acid sequence shown in SEQ ID NO: 135 and a heavy chain having the amino acid sequence shown in SEQ ID NO: 134, or
a light chain having the amino acid sequence shown in SEQ ID NO: 132 and a heavy chain having the amino acid sequence shown in SEQ ID NO: 133.
3. A pharmaceutical composition, comprising said antibody of claim 2 and a pharmaceutically acceptable carrier, diluent, or excipient.
4. The pharmaceutical composition of claim 3 , wherein said antibody is present in an amount of from about 20 to about 100 mg/ml.
5. The pharmaceutical composition of claim 3 , wherein said antibody comprises a light chain having the amino acid sequence shown in SEQ ID NO: 135 and a heavy chain having the amino acid sequence shown in SEQ ID NO: 134.
6. The pharmaceutical composition of claim 3 , wherein said antibody comprises a light chain having the amino acid sequence shown in SEQ ID NO: 132 and a heavy chain having the amino acid sequence shown in SEQ ID NO: 133.
7. The pharmaceutical composition of claim 3 , comprising a surfactant.
8. The pharmaceutical composition of claim 7 , wherein said surfactant is polysorbate 80.
9. The pharmaceutical composition of claim 8 , wherein said polysorbate 80 is present in an amount of from about 0.005% to about 0.05% by weight.
10. The pharmaceutical composition of claim 3 , comprising a citrate buffer at a pH range of from about 5.5 to about 7.0.
11. The pharmaceutical composition of claim 10 , wherein said citrate buffer is present in a concentration of about 10 mM sodium citrate at a pH range of from about 5.5 to about 7.0.
12. The pharmaceutical composition of claim 11 , wherein said pH is about 6.0 to about 6.5.
13. The pharmaceutical composition of claim 3 , comprising about 50 to about 150 mM sodium chloride.